Nomura Asset Management Co. Ltd. increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 6.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,460 shares of the medical equipment provider’s stock after acquiring an additional 1,914 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Zimmer Biomet were worth $3,675,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Longview Partners Guernsey LTD lifted its stake in shares of Zimmer Biomet by 6.9% in the fourth quarter. Longview Partners Guernsey LTD now owns 8,027,808 shares of the medical equipment provider’s stock worth $968,716,000 after acquiring an additional 521,124 shares during the period. Nordea Investment Management AB lifted its stake in shares of Zimmer Biomet by 7.3% in the third quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock worth $617,961,000 after acquiring an additional 357,302 shares during the period. American Century Companies Inc. lifted its stake in shares of Zimmer Biomet by 14.7% in the fourth quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after acquiring an additional 612,044 shares during the period. Jana Partners LLC lifted its stake in shares of Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after acquiring an additional 662,497 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Zimmer Biomet by 24.4% in the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock worth $323,134,000 after acquiring an additional 541,102 shares during the period. 86.64% of the stock is currently owned by institutional investors.
A number of equities analysts recently commented on the company. BMO Capital Markets reaffirmed a “buy” rating and issued a $144.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, January 30th. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $120.00 to $168.00 in a research note on Wednesday, January 31st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, January 30th. Robert W. Baird reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, January 31st. Finally, Leerink Swann lifted their price objective on Zimmer Biomet from $142.00 to $146.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $141.06.
Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $117.92 on Wednesday. The firm has a market capitalization of $23,880.00, a P/E ratio of 13.25, a price-to-earnings-growth ratio of 2.13 and a beta of 1.13. The company has a quick ratio of 0.81, a current ratio of 1.50 and a debt-to-equity ratio of 0.76. Zimmer Biomet Holdings Inc has a 1-year low of $108.03 and a 1-year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.10. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.14 earnings per share. equities analysts anticipate that Zimmer Biomet Holdings Inc will post 7.8 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.81%. Zimmer Biomet’s payout ratio is currently 10.79%.
TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/14/nomura-asset-management-co-ltd-purchases-1914-shares-of-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.